Dr. Helmuth van Es, CEO. Helmuth is a co-founder of Galapagos, where he was Head of Science in Leiden, responsible for numerous discovery programmes many of which are now in clinical development. He co-founded Audion Therapeutics, Antabio, Effecta Pharma and Citryll. Audion Therapeutics is a clinical stage company focussed on small molecule treatments for acquired forms of hearing loss based in part on IP of co-founder Albert Edge at the MEEI in Boston. Eli Lilly and Inkef are investors in Audion. He is non-executive director of Antabio ― a small molecule antibacterial company with headquarters in France. Effecta is a small molecule discovery company focussing on dengue and related viral infections.
Renato Chirivi, Ph.D., CSO. Renato is responsible for the scientific strategy of Citryll’s tACPA programmes. He is co-inventor of the tACPA antibodies and as such is an expert on antibody discovery, development and production, protein citrullination, and NET biology. He has over 20 years’ experience in cancer, neurobiology and molecular immunology.
Marlon Dijkshoorn M.Sc., CFO. Marlon is founding partner of F.institute, a full service finance boutique dedicated to companies in the life sciences sector. Having more than 25 years of experience in financial management from large enterprises to venture funds and small technology companies, he acts as part time CFO for Citryll. Next to Citryll, Marlon is also CFO of other leading life science ventures. He provides critical support in raising capital investments and delivering high quality information to all stakeholders.
Maarten van der Linden, Ph.D., Scientist NETosis biology. Maarten performed his Ph.D. research at the University Medical Center Utrecht (The Netherlands), Laboratory of Translational Immunology under supervision of Professor Linde Meyaard, working on immune regulation in autoimmune diseases with the focus on inhibitory receptors and NETosis. Maarten is responsible for further unravelling the mechanism of action (MoA) of Citryll’s antibody drug candidate, the incorporation of new MoA insight into the drug development plan and identifying new therapeutic applications for tACPA.